Clinical Trials Logo

Pancreas Cancer clinical trials

View clinical trials related to Pancreas Cancer.

Filter by:

NCT ID: NCT04747600 Completed - Pancreas Cancer Clinical Trials

Outcomes of Surgical Resection of Pancreatic Cystic Neoplasms Based on the European Expert Consensus Statement: A Prospective Observational Study.

Start date: June 1, 2014
Phase:
Study type: Observational

Introduction: Pancreatic cystic neoplasms (PCNs) comprise neoplasms with a wide range of benign and malignant varieties. The most common include serous cystic neoplasms (SCNs), mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and solid pseudo-papillary neoplasms (SPPNs). Endoscopic ultrasonography (EUS), computed tomography (CT) and magnetic resonance (MR) are used to diagnose different PCNs types. The cyst fluid aspiration and analysis is performed in difficult differential diagnosis. Frequently, amylase and CEA levels are measured. The choice of surgery depends on cyst location and size and includes pancreatico-duodenectomy or distal pancreatectomy. Objectives: The aim of this study was to evaluate the outcomes after pancreatic surgery when adopted as the management of true exocrine epithelial cystic neoplasms.

NCT ID: NCT04542291 Completed - Pancreatic Cancer Clinical Trials

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Start date: February 25, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.

NCT ID: NCT04528745 Completed - Colorectal Cancer Clinical Trials

The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients

Start date: May 4, 2020
Phase:
Study type: Observational [Patient Registry]

An observational study of the relationship between fat free mass and toxicity of cytostatics in cancer patients, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark. Fat free mass will be measured by bio impedance spectroscopy and data on toxicity will be obtained from medical records and interviews/questionnaires with the patients.

NCT ID: NCT04385147 Completed - COVID-19 Clinical Trials

Advanced Endoscopy During COVID-19

Start date: May 18, 2020
Phase:
Study type: Observational

In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.

NCT ID: NCT04361682 Completed - Pancreas Cancer Clinical Trials

Preoperative Inflammatory Biomarkers and Postoperative Day 1 Drain Amylase Value Predict Pancreatic Fistula After Pancreaticoduodenectomy

Start date: January 1, 2005
Phase:
Study type: Observational

Particularly, pancreatic fistula is the most common and serious complication after pancreaticoduodenectomy (PD) and is reported in up to 40% of cases. The aim of this retrospective single-center study was to investigate the utility of the combination of preoperative inflammation biomarkers (PIBs) with postoperative day 1 drains amylase (POD1-d.a.) levels in predicting grade C Pancreatic Fistula (PF).

NCT ID: NCT04341909 Completed - Pancreas Cancer Clinical Trials

Trainee Involvement in ERCP Risk Score

TIERS
Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

The study aims to evaluate factors associated with an increased risk of procedure related adverse events (including tecnical failure) of endoscopic retrograde cholangiopancreatography procedures (ERCP) conducted in a teaching setting, with trainee involvement.

NCT ID: NCT04316078 Completed - Gastric Cancer Clinical Trials

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

Start date: March 15, 2020
Phase: N/A
Study type: Interventional

A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.

NCT ID: NCT04191928 Completed - Pulmonary Embolism Clinical Trials

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

PAP-UP
Start date: March 3, 2020
Phase: Phase 1
Study type: Interventional

Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of the duodenum.

NCT ID: NCT04080024 Completed - Breast Cancer Clinical Trials

A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer

SPAGOPIX-01
Start date: August 23, 2019
Phase: Phase 1
Study type: Interventional

This phase I, first-in-human (FIH) study is open-label, non-randomised and non-placebo-controlled. The study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of a single intravenous dose of SN132D in approximately 24 patients with breast and pancreatic cancer. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.

NCT ID: NCT04064034 Completed - Pancreas Cancer Clinical Trials

ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.